Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Patent
1998-11-12
2000-11-21
Seaman, D. Margaret
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
546155, 514253, 514312, A61K 3150, A61K 3147, C07D23970, C07D21516
Patent
active
061505226
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The gonadotropin-releasing hormone (GnRH), also referred to as luteinizing hormone-releasing hormone (LHRH), is a decapeptide that plays a key role in human reproduction. The hormone is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH released from the pituitary gland is primarily responsible for the regulation of gonadal steroid production in both sexes, whereas FSH regulates spermatogenesis in males and follicular development in females. GnRH agonists and antagonists have proven effective in the treatment of certain conditions which require inhibition of LH/FSH release. In particular, GnRH-based therapies have proven effective in the treatment of endometriosis, uterine fibroids, polycystic ovarian disease, precocious puberty and several gonadal steroid-dependent neoplasia, most notably cancers of the prostate, breast and ovary. GnRH agonists and antagonists have also been utilized in various assisted fertilization techniques and have been investigated as a potential contraceptive in both men and women. They have also shown possible utility in the treatment of pituitary gonadotrophe adenomas, sleep disorders such as sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, hirsutism, as an adjunct to growth hormone therapy in growth hormone deficient children, and in murine models of lupus. The compounds of the invention may also be used in combination with bisphosphonates (bisphosphonic acids) and other agents, such as growth hormone secretagogues, e.g. MK-0677, for the treatment and the prevention of disturbances of calcium, phosphate and bone metabolism, in particular, for the prevention of bone loss during therapy with the GnRH antagonist, and in combination with estrogens, progesterones, antiestrogens, antiprogestins and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with the GnRH antagonist.
Additionally, a compound of the present invention may be co-administered with a 5.alpha.-reductase 2 inhibitor, such as finasteride or epristeride; a 5.alpha.-reductase 1 inhibitor such as 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one, 3-oxo-4-aza-4,7.beta.-dimethyl-16.beta.-(4-chlorophenoxy)-5.alpha.-androst ane, and 3-oxo-4-aza-4,7.beta.-dimethyl-16.beta.-(phenoxy)-5.alpha.-androstane as disclosed in WO 93/23420 and WO 95/11254; dual inhibitors of 5.alpha.-reductase 1 and 5.alpha.-reductase 2 such as 3-oxo-4-aza-17.beta.-(2,5-trifluoromethylphenyl-carbamoyl)-5.alpha.-andros tane as disclosed in WO 95/07927; antiandrogens such as flutamide, casodex and cyproterone acetate, and alpha-1 blockers such as prazosin, terazosin, doxazosin, tamsulosin, and alfuzosin.
Further, a compound of the present invention may be used in combination with growth hormone, growth hormone releasing hormone or growth hormone secretagogues, to delay puberty in growth hormone deficient children, which will allow them to continue to gain height before fusion of the epiphyses and cessation of growth at puberty.
Current GnRH antagonists are GnRH-like decapeptides which are generally administered intravenously or subcutaneously presumably because of negligible oral activity. These have amino acid substitutions usually at positions one, two, three, six and ten.
Non-peptide GnRH antagonists offer the possible advantage of oral adminstration. Non-peptide GnRH antagonists have been described in European Application 0 219 292 and in De, B. et al., J. Med. Chem., 32, 2036-2038 (1989), in WO 95/28405, WO 95/29900 and EP 0679642 all to Takeda Chemical Industries, Ltd.
Arylquinolone analogs have been described in the art and include those described in the following patents, patent applications and journal articles. JP-A-63-295561 discloses a class of 3-phenyl-2(1H)-quinolone derivatives, substituted at the 4-position by an unsubstituted straight or branched alkoxy group and at the 7-positi
REFERENCES:
patent: Re34722 (1994-09-01), Uchida et al.
patent: 4284768 (1981-08-01), Santilli
patent: 5614532 (1997-03-01), Carling et al.
patent: 5656643 (1997-08-01), Spada et al.
J. Med. Chem, vol. 32, pp. 2036-2038 (1989), by Clark, et al.
J. Heterocyclic Chem, vol. 26, pp. 281-284 (1989), by Yamaguchi, et al.
Monatshefte Fur Chemie, vol. 113, pp. 751-760 (1982), by Stadlbauer, et al.
Vestn. Slov. Kem. Drus., vol. 33, No. 3, pp. 271-281 (1986), by Stadlbauer, et al.
Annu. Rev. Med., vol. 45, pp. 391-405 (1994), by Conn, et al.
Current Opinion in Obstet. & Gyno., vol. 6, pp. 262-268 (1994), by R. Loy.
TEM, vol. 3, No. 1, pp. 30-34 (1992), by R. Barbieri.
Drugs, vol. 35, pp. 63-82 (1988), by Filicori, et al.
Human Reproduction, vol. 11, Suppl., pp. 89-101 (1996), by U. Cirkel.
Human Reproduction, vol. 11, Suppl., pp. 123-132 (1996), by G. Hodgen.
Devita Robert J.
Goulet Mark
Wyvratt, Jr. Matthew J.
Young Jonathan R.
Daniel Mark R.
Korsen Elliott
Merck & Co. , Inc.
Seaman D. Margaret
LandOfFree
Antagonists of gonadotropin releasing hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of gonadotropin releasing hormone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of gonadotropin releasing hormone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1258716